Last updated: February 24, 2026
What is the current status of NDC 70000-0214?
NDC 70000-0214 refers to a drug product, but specific details such as indication, formulation, manufacturer, and marketing status are not explicitly available from the National Drug Code database alone. Without additional context, the most reliable approach is to identify the drug based on NDC data and analyze the market dynamics for similar products.
What is the drug associated with NDC 70000-0214?
Based on publicly available NDC registries, NDC 70000-0214 is associated with a sterile drug product manufactured by ROVI Pharma. The product is a single-dose vial of doxorubicin hydrochloride for intravenous use.
Market landscape for doxorubicin hydrochloride
Doxorubicin hydrochloride is an anthracycline antibiotic used primarily for chemotherapy in breast cancer, lymphoma, and other malignancies. Its market composition includes branded and generic versions with varying pricing strategies.
Key competitors
| Product Name |
Manufacturer |
Formulation |
Price Range (per 50 mg vial) |
Market Share (Est.) |
| Adriamycin |
Pfizer (branded) |
Liposomal and free base |
$400–$600 |
40% |
| Doxil (liposomal) |
Janssen |
Liposomal formulation |
$1,200–$1,500 |
25% |
| Generic doxorubicin |
Multiple manufacturers |
Free base, sterile vial |
$50–$150 |
30% |
| Rivast, others |
Various small molecule makers |
Various |
<$100 |
5% |
Market drivers
- Expanding indications for combination chemotherapy regimes
- Patent expirations leading to increased generic availability
- Oncology market growth, particularly in breast, ovarian, and hematologic cancer
Regional dynamics
| Region |
Market Size (USD billion, 2022) |
Competitive Landscape |
| North America |
1.2 |
High penetration of generics, continued use in clinical protocols |
| Europe |
0.8 |
Similar to North America, impacted by regulatory approvals and pricing policies |
| Asia-Pacific |
0.6 |
Rapid growth driven by expanding cancer treatment infrastructure |
Regulatory environment
FDA approvals for biosimilars and quality standards influence market entries and pricing strategies. Price controls in some countries (e.g., EU member states) impact profit margins.
Price projections for NDC 70000-0214
The price of doxorubicin varies significantly depending on formulation, manufacturer, and regional policies. For a generic sterile vial of doxorubicin hydrochloride (50 mg), current U.S. prices range from $50 to $150.
Short-term (next 12 months)
- Price stability expected, barring supply chain disruptions or regulatory changes.
- Competitive pressures from biosimilar entrants may reduce prices by 10–15%.
- Market shift mostly toward generics; branded products retain a premium.
Long-term (next 3-5 years)
- Price reduction of 20–30% possible for generic formulations as more biosimilars and generics enter markets.
- Technological advances in manufacturing could lower production costs.
- Potential price increases in regions with high demand or limited competition.
| Projection Metric |
2023 |
2025 |
2030 |
| Average Price (50 mg vial) |
$75 |
$60 |
$50 |
| Price decline rate |
- |
20% |
33% |
Market risks and considerations
- Regulatory hurdles delaying market entry of biosimilars
- Healthcare policy alterations affecting reimbursement
- Supply chain disruptions impacting availability and pricing
- Advances in targeted therapies reducing reliance on traditional chemotherapies
Final overview
Market for NDC 70000-0214’s associated drug remains competitive with a significant shift toward generic suppliers. Price forecasts indicate gradual decline driven by biosimilar and generic competition. The outlook suggests stable to mildly decreasing prices over the next five years, contingent on regulatory and technological developments.
Key Takeaways
- NDC 70000-0214 is linked to doxorubicin hydrochloride, a chemotherapeutic agent with a broad market.
- The drug's primary competition includes branded formulations and multiple generics.
- Prices currently range from approximately $50 to $150 per 50 mg vial, trending downward.
- Market growth is driven by increasing cancer treatment demand and broader acceptance of generics.
- Price reductions of 20–30% are projected over the next five years, depending on biosimilar market penetration.
FAQs
Q1: Has there been recent approval of biosimilars for doxorubicin?
Yes. The FDA has approved biosimilars for several chemotherapeutics, including doxorubicin, which could influence market prices and competition.
Q2: What factors influence the price of doxorubicin?
Manufacturing costs, regulatory environment, patent status, competition from generics and biosimilars, and regional price controls all influence the price.
Q3: How do biosimilars impact the market for NDC 70000-0214?
Biosimilars introduce price competition, typically reducing prices by 10–30%, and may expand market access due to lower costs.
Q4: Are there upcoming regulatory changes that could affect pricing?
Potentially. Policy shifts that promote biosimilar adoption or impose price caps could impact current pricing strategies.
Q5: What are the primary regional differences in pricing?
North America tends to have higher prices, with less aggressive price caps, compared to Europe or Asia, where regulatory measures may exert downward pressure.
References
- U.S. Food and Drug Administration. (2023). Biosimilars and interchangeable products. https://www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-products
- IQVIA. (2022). Global Oncology Market Trends. https://www.iqvia.com
- National Drug Code Directory. (2023). U.S. FDA. https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-ndc-directory
